Drug intelligence / Profile preview

G1090N

Development stage: Phase 1
Lead developer: Genfit
Modality: Small Molecules

Overview

G1090N is a new drug candidate developed by GENFIT, first introduced in 2024 as part of their pipeline targeting acute-on-chronic liver failure (ACLF). It represents a novel formulation within GENFIT's ACLF franchise, which includes several assets with complementary mechanisms of action and different routes of administration. The specific mechanism of action for G1090N has not been publicly disclosed as of June 2025. The drug is currently being evaluated in clinical trials for ACLF, and no additional indications or detailed pharmacological information are available at this time[2][4][6][7].

Other names: G1090N/NTZnitazoxanide reformulation

Targets

NQO1

Beyond the preview

Go deeper on G1090N.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G1090N.

Explore the full profile